Alessandro Lucchesi: The Future of MPN Disease Modification
Alessandro Lucchesi, Consultant Hematologist at Romagna Scientific Institute for the Study and Treatment of Cancer (I.R.S.T.) Ltd., shared a post on LinkedIn:
“Can we engineer disease trajectories in MPNs?
That is the question RiseMPN 2026 will spend two days trying to answer.
The therapeutic toolkit in myeloproliferative neoplasms is expanding faster than our ability to position it.
JAK inhibition transformed symptom control but only partially delivered on disease modification.
Interferons, hepcidin-axis agents, epigenetic modulators, p53/MDM2 strategies, activin ligand traps – the question is no longer what works.
It is which combinations, in which patients, at which time-point, can genuinely rewrite the natural history of disease.
Rome, 6–7 November 2026.
Single track.
No parallel sessions.
Forty speakers from ten countries.
A transatlantic Strategic Dialogue, two Rise Lectures, a Preclinical Spotlight pairing senior tutors with our 2025 Best Abstract winners, and the Rise Ritual – because the best conversations happen when the slides stop.
Call for abstracts closes 20 October 2026.
Registration is free.
ECM accredited.”
Stay updated with Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:39David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:34The Changing Landscape of Anticoagulant Therapy – ISTH
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters